Vincristine (NSC-67574) sulfate

Name: Vincristine (NSC-67574) sulfate
Brand: Selleck Chemicals
SKU: S1241
Rating: 5 (79 reviews)

For research use only.

Catalog No.S1241 Synonyms: Leurocristine, Oncovin, 22-Oxovincaleukoblastine

79 publications

Vincristine (NSC-67574) sulfate Chemical Structure

CAS No. 2068-78-2

Vincristine sulfate (NSC-67574, Leurocristine, Oncovin, 22-Oxovincaleukoblastine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.

Selleck's Vincristine (NSC-67574) sulfate has been cited by 79 publications

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Theranostics, 2021, 11(9):4281-4297

PubMed: 33754061 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-20-0864

PubMed: 33850006 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01003-3

PubMed: 33475937 ( click the link to review the publication )

Chem Biol Interact, 2021, 340:109448

PubMed: 33775687 ( click the link to review the publication )

Toxicol Lett, 2021, 340:67-76

PubMed: 33429010 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2021, mcs.a006049

PubMed: 33722797 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-1315

PubMed: 32826328 ( click the link to review the publication )

Oncogene, 2020, 39(17):3555-3570

PubMed: 32123312 ( click the link to review the publication )

Environ Sci Technol, 2020, 54(23):15267-15276

PubMed: 33201683 ( click the link to review the publication )

Cancer Lett, 2020, 469:111-123

PubMed: 31639426 ( click the link to review the publication )

J Pathol, 2020, 10.1002/path.5591

PubMed: 33206391 ( click the link to review the publication )

BMC Biol, 2020, 22;18(1):42

PubMed: 32321486 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02933-w

PubMed: 33057863 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 17;14(4):e0008224

PubMed: 32302296 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxicology, 2020, 429:152329

PubMed: 31733235 ( click the link to review the publication )

Vet Comp Oncol, 2020, 10.1111/vco.12656

PubMed: 33025640 ( click the link to review the publication )

Biol Open, 2020, bio.050211

PubMed: 33372065 ( click the link to review the publication )
Cell Biol Int, 2020, 44(2):610-620

PubMed: 31743535 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Med Rep, 2020, 22(4):2791-2800

PubMed: 32945456 ( click the link to review the publication )

Neuroreport, 2020, 31(3):197-204

PubMed: 31834144 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

Int J Med Sci, 2020, 17(11):1652-1664

PubMed: 32669967 ( click the link to review the publication )

Cancer Res, 2019, 79(20):5382-5393

PubMed: 31405846 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1544-1556

PubMed: 30726737 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 31742555 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6175

PubMed: 31817853 ( click the link to review the publication )

J Cell Biochem, 2019, 120(10):17791-17810

PubMed: 31264739 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

J Exp Med, 2018, 215(8):2137-2155

PubMed: 30045945 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1070

PubMed: 30341283 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

J Exp Med, 2018, 215(12):3094-3114

PubMed: 30404791 ( click the link to review the publication )
Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(10):2506-2515

PubMed: 27780854 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(8):1555-1565

PubMed: 28522589 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(24):39064-39076

PubMed: 28388564 ( click the link to review the publication )

Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245981 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )
Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Int J Anal Chem, 2015, 2015:743915

PubMed: 27034675 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Targets

Microtubules ^[1]
(Cell-free assay)

32 μM

In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with K_i of 85 nM. ^[1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. ^[2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. ^[4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	NVjrdXZ1S2WubDDWbYFjcWyrdImgRZN{[Xl?	M3zJcFAuOC53IN88US=>	M1flOFI1KGh?		NYDQd2tS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=	M2\F[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	MXvBdI9xfG:\|aYOgRZN{[Xl?	NVXRb4I5OC1yLkWg{txO	NE\uc2szPCCq		MmTPbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	NF:1fGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2N\|c3QSd-MkW2OlM4Pjl:L3G+
HepG2.2.15	M2rtfWZ2dmO2aX;uJGF{e2G7	MlnpNE4yKM7:TR?=	Mli5NlQhcA>?		NIfVUJNxem:vb4Tld{Bp\XCjdHn0bZMhSiC4aYL1d{Bxem:2ZXnuJIV5eHKnc4Ppc44>	NXr3SFB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OlM4PjlpPkK1OlY{PzZ7PD;hQi=>
HepG2-HBV1.1	NXT0O2U1TnWwY4Tpc44hSXO\|YYm=	NIW1U\|cxNjFizszN	M3LTPFI1KGh?		MYrwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36=	M4PlW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	NIjJdFZHfW6ldHnvckBCe3OjeR?=	NF3pRZQxNjFizszN	M1jDZlQ5KGh?		NXTLWZFNeHKxbX;0[ZMh[2WubDDlfINz\XSrb36gc4YhcGWyYYTpeIl{KEJidnnyeZMhdnWlbHXvZ4Fxe2mmczDpcpN1\WGmIH;mJIhmeGG2aYTpd{BDKH[rcoXzJGRidmVicHHyeIlkdGW\|	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NkO3OlkoRjJ3Nk[zO\|Y6RC:jPh?=
HepG2-HBV1.1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\SRXMxNjFizszN	M4j3NFEuPSCm		M1TjPYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm=	M3ftOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojENE4yKM7:TR?=	MmLINU02KGR?		M2HGUolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm=	M1GyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[zO\|Y6Lz5{NU[2N\|c3QTxxYU6=
HepG2-HBV1.1	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrZVXgxNjFizszN	MYqxNk04OiCq		NETW[pRqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ4M{e2PUc,OjV4NkO3Olk9N2F-
HepG2-HBV1.1	M2TMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjtNWcxNjFizszN	MV6xNk04OiCq		NWDIPW9XcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm	MnTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NkO3OlkoRjJ3Nk[zO\|Y6RC:jPh?=
Raji	M4m5VmZ2dmO2aX;uJGF{e2G7	NFLMZmcxNjYEoN88US=>	MoXLO\|IhcA>?		NHK3NZFi[m:uaYPo[ZMh[XW2b4DoZYd6yqB?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NkO3O{c,OjV2NE[zO\|c9N2F-
SK-MEL-28	NWmxUI94TnWwY4Tpc44hSXO\|YYm=	MmH3N\|Ahdk1?	M1zN[\|YhcA>?		NX\wfYI6cW6mdXPld{BIOuLCk12gZ4VtdC2leXPs[UBienKnc4S=	M3;wb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{GzNFExLz5{NUOxN\|AyODxxYU6=
H157	NXnPV2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHNdFhKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?=	M1zwN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkW3PVEyLz5{NUK1O\|kyOTxxYU6=
Jurkat	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfyOHEyNTNibl2=	NGfIVpk1QMLiaB?=	MYLEUXNQ	NHLwcGFl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6	M{DBZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUW2NVQ3Lz5{NUG1OlE1PjxxYU6=
CEM	NF;pXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDWb2kyNTNibl2=	NFjnPJY1QMLiaB?=	NG\oTpBFVVOR	M1j1dIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk>	MoW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNU[xOFYoRjJ3MUW2NVQ3RC:jPh?=
P12	M2H1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3WNU0{KG6P	M4nVUFQ5yqCq	MVnEUXNQ	MYLk[YNz\WG\|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3NkG0Okc,OjVzNU[xOFY9N2F-
KB	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHtWFVKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN	M3;EXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEW4OVI3Lz5{NUC1PFUzPjxxYU6=
KBv200 (ABCB1)	M13VZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTBwM{S2NkDDuSByLkCwOlYh\|ryP	MkPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUi1NlYoRjJ3MEW4OVI3RC:jPh?=
SUDHL6	NF60UIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGx5qCK\|ryP	M{PNR\|Q5Nzd{IHi=		MYfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC\|aXfubYZq[2GwdHz5	Ml7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkG2NFQoRjJ2OU[xOlA1RC:jPh?=
SUDHL6	M1TzR2Z2dmO2aX;uJGF{e2G7	MoPTNgKBkc7:TR?=	MVi3NkBp		MVvpcoR2[2W\|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C	NU\VPGdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE3ODRpPkK0PVYyPjB2PD;hQi=>
HCT-116	NHfOZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHuOohIUTVyPUWgcm0>	M{HGU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUK3PFU4Lz5{NEmyO\|g2PzxxYU6=
SKNBe2C	NWDCfJFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlWzTWM2OD1\|Mj64xtE1NjBibl2=	M1vDeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUKxPVIxLz5{NEmyNVkzODxxYU6=
IGNR91	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zlTGlEPTB;MkSuN:KyOS55IH7N	NVTDT44{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NlE6OjBpPkK0PVIyQTJyPD;hQi=>
SKNAS	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjxUXFKSzVyPUGuOeKyOC5{IH7N	M{TX[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUKxPVIxLz5{NEmyNVkzODxxYU6=
LAN1	NEf2VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJwM9MxNE4zKG6P	MoTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
SHSY5Y	NHLxR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILCPXRKSzVyPUiuNuKyOC54IH7N	Mn7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MkG5NlAoRjJ2OUKxPVIxRC:jPh?=
A549-WT	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTF7LkSzO{DDuSByLkW5OEAhdk1?	NILJTo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1PFgzPyd-MkS4OVg5Ojd:L3G+
A549-R	NInlOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlj5TWM2OD1zMj6xO\|ghyrFiMD6zN\|MhKG6P	MnPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUi4NlcoRjJ2OEW4PFI4RC:jPh?=
MCF-7-WT	M13hTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\s[4ZkUUN3ME2xO{44PTJiwsGgNE4zOThiIH7N	Mk\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUi4NlcoRjJ2OEW4PFI4RC:jPh?=
MCF-7-R	M1nuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLQeGdKSzVyPUWuOVM6KMLzIECuNVQ1KCCwTR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3OEiyO{c,OjR6NUi4Nlc9N2F-
A549-R	M1zVc2N6fG:2b4jpZ4l1gSCDc4PhfS=>				M2rZN2lEPTB;MUKuNVc5KMLzIECuN\|M{KG6P	NHnUTJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1PFgzPyd-MkS4OVg5Ojd:L3G+
MCF-7-R	MnL1R5l1d3SxeHnjbZR6KEG\|c3H5				M3LNN2lEPTB;NT61N\|khyrFiMD6xOFQhdk1?	M{DoSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW4PFI4Lz5{NEi1PFgzPzxxYU6=
SW620	NGHxTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLpTWM2OD15LkiwJOKyKDBwMEigcm0>	NXjwNJMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlY4OzlpPkK0O\|I3PzN7PD;hQi=>
SW620/AD300	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXUeXl{UUN3ME25NFkvPjBiwsGgPE46OSCwTR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{NkezPUc,OjR5Mk[3N\|k9N2F-
HEK293/pcDNA3.1	MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHznOW1KSzVyPUGuOFUhyrFiMD6yNEBvVQ>?	MmDXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mk[3N\|koRjJ2N{K2O\|M6RC:jPh?=
HEK293/ABCC1	M2HiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF7LkK5JOKyKDJwMEigcm0>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{NkezPUc,OjR5Mk[3N\|k9N2F-
TCC	NHHlRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NITCVnczPCCq		NHXHRmxKSzVyPUewJI5O	Ml;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MU[5OFQoRjJ2N{G2PVQ1RC:jPh?=
TCC	NUjndGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEjLXo01QCCq		NX\YTIlOUUN3ME21NEBvVQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDdzNkm0OEc,OjR5MU[5OFQ9N2F-
HepG2/ADM	NYDudGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEX0RoVKSzVyPUKuO\|g3O8LzMD6yN\|cyKM7:TR?=	M3XYTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{C0OVU3Lz5{NEewOFU2PjxxYU6=
HepG2	NHy3Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTBwMEGxOeKyOC5yMEG3JO69VQ>?	NIrZ[lg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOFU2Pid-MkS3NFQ2PTZ:L3G+
MCF-7/ADR	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVv1OIlzUUN3ME20MlQ5OjcEsUCuNlA4OCEQvF2=	NVHjdmx2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NFQ2PTZpPkK0O\|A1PTV4PD;hQi=>
MCF-7	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rEPWlEPTB;MD6wNVU6yrFyLkCwOlIh\|ryP	NEjjU5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEewOFU2Pid-MkS3NFQ2PTZ:L3G+
A-172	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfuNE4yyqEQvF2=	MlG2NlQwPzJiaB?=		MXzpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	NWjFS2FNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|AzOzVpPkK0OVMxOjN3PD;hQi=>
U-251MG	NEL3b4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLSdY5xOC5zwrFOwG0>	Mlm1NlQwPzJiaB?=		NIX1VG9qdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	NXnRcW9XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|AzOzVpPkK0OVMxOjN3PD;hQi=>
DLD-1	MmHkSpVv[3Srb36gRZN{[Xl?	MX2xNFAhdk1?	M2PDTlQ5KGh?		NUjmU\|I6eHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi	NUP0fnVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFM1PTNpPkK0OFA{PDV\|PD;hQi=>
CCD18Co	NHyzSpRHfW6ldHnvckBCe3OjeR?=	NYezRW1jOTByIH7N	MmHjOFghcA>?		MXrwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA>	MmjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEO0OVMoRjJ2NECzOFU{RC:jPh?=
DLD-1	NYLW[3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXmbYsxNTFyMECgcm0>	MoLDOFghcA>?		M1LKXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	NF3aSWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwN\|Q2Oyd-MkS0NFM1PTN:L3G+
CCD18Co	NV7JNnJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf5e4FGOC1zMECwJI5O	MXG0PEBp		NUjoS2FkcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	M4PZRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NECzOFU{Lz5{NESwN\|Q2OzxxYU6=
HepG2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFfKdHUzPCCq		NWTO[5FOUUN3ME21Nk426oDLzszN	MmjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NEG2PFgoRjJ2M{SxOlg5RC:jPh?=
HEK293/pcDNA3.1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jtbmlEPTB;MD6wNFTDuTBwMECwN{DPxE1?	MkPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OES3PFMoRjJ2Mki0O\|g{RC:jPh?=
HEK293/MRP1	Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPFd2tYUUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?=	M3\je\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mki0O\|g{Lz5{NEK4OFc5OzxxYU6=
Ramos	M1rSU2Fxd3C2b4Ppd{BCe3OjeR?=	MW[y5qCK\|ryP	MoHnOFghcA>?		NELBTWdqdmS3Y3XzJFM1NjZnwsGxMlkzLSCjcH;weI9{cXN?	MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NU[0PVEoRjJ2MkW2OFkyRC:jPh?=
NCI-H1299/pcDNA3	M3f4dGNmdGxiVnnhZoltcXS7IFHzd4F6	NVO3UXBGOC1{MDDuUS=>	M1rRXlk3KGh?		NXXlSohJcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NVPvcnpORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|cxOTJpPkK0NVc4ODF{PD;hQi=>
H1299/ICAM-3	MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXXvR4JxOC1{MDDuUS=>	MnzrPVYhcA>?		M1HmWIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NVvtfYNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|cxOTJpPkK0NVc4ODF{PD;hQi=>
NCI-H1299/pcDNA3	NHuwPG5HfW6ldHnvckBCe3OjeR?=	M1rxeFEwPS9zMD:yNOKhdk1?	NHvrbHE6PiCq		MYLpcoR2[2W\|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ	MoXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{ewNVIoRjJ2MUe3NFEzRC:jPh?=
H1299/ICAM-3	MoDFSpVv[3Srb36gRZN{[Xl?	Mn7hNU82NzFyL{KwxsBvVQ>?	NELLNWQ6PiCq		Mo\hbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=>	M{e0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe3NFEzLz5{NEG3O\|AyOjxxYU6=
W1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X0eWlEPTB;MD6wNFMzKM7:TR?=	M4nhZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUSwNVc3Lz5{NEG0NFE4PjxxYU6=
W1VR	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFOzPIFKSzVyPUCuNFU3KM7:TR?=	NUD2RnpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFAyPzZpPkK0NVQxOTd4PD;hQi=>
K562	NYrkT25vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTBwMEOyJOKyKDBwMECxJEDPxE1?	NGjuUo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOVk{Pyd-MkSxN\|U6Ozd:L3G+
K562/ADR	NGjoRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXoVoJKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?=	NV\SNG85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|U6OzdpPkK0NVM2QTN5PD;hQi=>
K562	MVXBdI9xfG:\|aYOgRZN{[Xl?	NGS5cW0xNjNizszN	MXuyOEBp		Mk\xbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	NHXsVWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOVk{Pyd-MkSxN\|U6Ozd:L3G+
K562/ADR	MW\BdI9xfG:\|aYOgRZN{[Xl?	NVewSFFqOyEQvF2=	M2T3NVI1KGh?		Mm\CbY5lfWOnczDhdI9xfG:\|aYO=	NGXTXIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOVk{Pyd-MkSxN\|U6Ozd:L3G+
A549	NHXafXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnYPIVjUUN3ME2wMlExKMLzIECuNFMh\|ryP	MoHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7N{GwO\|UoRjJ\|OUexNFc2RC:jPh?=
K562	NY\MS49pS2WubDDWbYFjcWyrdImgRZN{[Xl?	M1mwdVMvPzYkgKO2NOKhdk1?	MYG3NuKhcMLi		M3vFcIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NUT1S4lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|czOjNpPkKzPFc4OjJ\|PD;hQi=>
lucena	MkDxR4VtdCCYaXHibYxqfHliQYPzZZk>	MVyzMlc26oDVNkFCpI5O	NHXOdYg4OsLiaNMg		NFnibnNvdyCnZn\lZ5Q>	NWfMS\|ZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|czOjNpPkKzPFc4OjJ\|PD;hQi=>
FEPS	MkO1R4VtdCCYaXHibYxqfHliQYPzZZk>	MVizMlc26oDVNkFCpI5O	MYW3NuKhcMLi		NX7OUIJEdm9iZX\m[YN1	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5N{KyN{c,OjN6N{eyNlM9N2F-
A2780	NFe2WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPLTWM2OD1\|LkWgcW0>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUKwN{c,OjN6MkmyNFM9N2F-
ACHN	M3W3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\WTWM2ODxyLkGgcW0>	M1XLU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5NlA{Lz5{M{iyPVIxOzxxYU6=
U-937	NX;TfGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRDN2IH7N	M1PEeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5NlA{Lz5{M{iyPVIxOzxxYU6=
Jurkat	NHXSWJdCeG:ydH;zbZMhSXO\|YYm=	NXXSVXdpPcLizsznM41tyqB?	NHvXUnAzPCCq		NInPblFqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	NX7RRmsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVA1ODlpPkKzPFExPDB7PD;hQi=>
Jurkat	M2fhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LRblXDqM7:Zz;tcOKh	MkPINlQhcA>?		NHWyfXhienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W=	MnTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MUC0NFkoRjJ\|OEGwOFA6RC:jPh?=
Hep-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFz1bWVKSzVyPUCuNFTDuTBwMEGg{txO	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd6MESyOEc,OjN5OEC0NlQ9N2F-
Hep-2/v	NFzzRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\SbFAzUUN3ME2xMljDuTBwMkCg{txO	NETGTog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4NFQzPCd-MkO3PFA1OjR:L3G+
SGC-7901	NGnBdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFH3eWsxNTFyIN88[{9udA>?	MmfZNlQwPDhxN{KgbC=>		MkHObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2M{W3Nkc,OjN5NEO1O\|I9N2F-
SGC-7901/VCR	NHv2ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGq3dlYxNTFyIN88[{9udA>?	M1fhflI1NzR6L{eyJIg>		MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2M{W3Nkc,OjN5NEO1O\|I9N2F-
SGC-7901	M1W3R2Fxd3C2b4Ppd{BCe3OjeR?=				NEntTlNqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M37aNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SzOVczLz5{M{e0N\|U4OjxxYU6=
SGC-7901/VCR	NFjGOHBCeG:ydH;zbZMhSXO\|YYm=				NWXZWHR3cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	NVHKTJVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFM2PzJpPkKzO\|Q{PTd{PD;hQi=>
KB-3-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rBdmlEPTB;MT62OkDDuSByLkG2NkDPxE1?	MnH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
KB-C2	NUXqcoFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XwdmlEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5M{S0OUc,OjN4N{O0OFU9N2F-
KB-3-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLhTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>?	Ml3yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
KB-V1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTZPWxoUUN3ME2yNFgvQDViwsGgNlAvPCEQvF2=	MlrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{O0OFUoRjJ\|NkezOFQ2RC:jPh?=
HEK293/pcDNA3.1	M1j0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDoTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>?	NUPpPGw5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|M1PDVpPkKzOlc{PDR3PD;hQi=>
HEK293/ABCB1	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYD3XmpFUUN3ME2zOVEzNjhiwsGgN\|c5NjN7MTFOwG0>	NXXPfZg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|M1PDVpPkKzOlc{PDR3PD;hQi=>
A549/EGFP	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGW3OXkxNjBzLUGwNFAh\|ryP			NWP0c45QUUN3ME24Ok44KMLzIEK5MlEh\|ryP	NEPmeW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[zOFI5Oid-MkO2N\|QzQDJ:L3G+
A549/Slug	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUWwMlAyNTFyMECg{txO			MoXyTWM2OD17LkegxtEhOy5zIN88US=>	NFLjUWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[zOFI5Oid-MkO2N\|QzQDJ:L3G+
JFCR39	M1L4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjMVIkyKML3TR?=	MkXqNlQhcA>?	M1jsdmROW09?	NFH1dFJu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy\|	NW\WTZJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVgzPzZpPkKzOVk5Ojd4PD;hQi=>
A549	NETtWlNHfW6ldHnvckBCe3OjeR?=	NYHtcVc5OTByIH7N	NHnQUFYyPiCq	NYjaS4tWTE2VTx?=	MX;s[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{	NYXXNpJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVgzPzZpPkKzOVk5Ojd4PD;hQi=>
SGC7901	M3WxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\rbGdKSzVyPUGuNlbjiIoEsfMAjVAvOTFizsznM41t	Mny4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/LV-NC	M2PIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rVUmlEPTB;MT63O-KBkcLz4pEJNE4yPiEQvHevcYw>	NWPGSmdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/LV-SGO1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\XTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=>	NVn3b441RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/VCR	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXDU4JKSzV\|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>?	NEfGbmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OFQ5Oid-MkO1OlQ1QDJ:L3G+
SGC7901/VCR-NC	M2rzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFSxfmFKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>?	Ml7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NkS0PFIoRjJ\|NU[0OFgzRC:jPh?=
SGC7901/VCR-si-SGO1	NIizdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfCbZFLUUN3ME22MlE56oDLwsJihKkyNjB\|IN88[{9udA>?	NXW4e2RURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/ADR	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE[xc5NKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t	NWDUXI1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SGC7901/ADR-NC	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRThwOURihKnDueLCiUCuOlgh\|rypL33s	NF7KSpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OFQ5Oid-MkO1OlQ1QDJ:L3G+
SGC7901/ADR-si-SGO1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTNwNEdihKnDueLCiUCuNlkh\|rypL33s	NVnlO4FVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlQ1QDJpPkKzOVY1PDh{PD;hQi=>
SH-SY5Y	NVm1d5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnj3NE4xODFvMUCg{txO	MWeyOEBp		M4i4fWlEPTB;MD6xNVPDuTBwMEGyJO69VQ>?	NW\KXXZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
SH-SY5Y	Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTINE4xODFvMUCg{txO	M1zZc\|Q5KGh?		NEDl[ZFKSzVyPUCuNFc5yrFyLkCwPUDPxE1?	NX3qOnQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlkxPjVpPkKzNVI6ODZ3PD;hQi=>
SH-SY5Y	NV\HVII3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLpV3QxNjByMT2xNEDPxE1?	NV\iN3NmPzJiaB?=		MnXDTWM2OD1yLkC1NeKyOC5yMEig{txO	M3L5Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
SH-SY5Y	M2rTXmFxd3C2b4Ppd{BCe3OjeR?=	NY\Jc205OC5zIN88US=>	MUSwMVI1KGh?		M{mzbYlv\HWlZYOgZZBweHSxc3nzJI9nKFOKLWPZOXkh[2WubIOg[o9tdG:5aX7nJINmdGxiY4njcIUh[XK{ZYP0JIF1KHSqZTDHNk9OKHCqYYPl	M4TmTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUK5NFY2Lz5{M{GyPVA3PTxxYU6=
SH-SY5Y	M2XFVWFxd3C2b4Ppd{BCe3OjeR?=	MX:wMlEh\|ryP	M1vsSFAuOjRiaB?=		NXG1VW9qcW6mdXPld{BucXSxdHnjJIFzemW\|dNMg	MoHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMkmwOlUoRjJ\|MUK5NFY2RC:jPh?=
LNCAP	M4O5PGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIrMZng4OiCqcoO=		NHHoXoJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjByMkmg{txONg>?	NGX1[WU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEezNlgxQSd-MkC3N\|I5ODl:L3G+
LNCAP	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NVHPPHE4PzJiaILz		M1fJTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvODB4MTFOwG0v	NHPYeVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVM1QCd-MkOyNVU{PDh:L3G+
PC3	NX3wU4djS3m2b4TvfIlkcXS7IHHzd4F6		NHrEfJc4OiCqcoO=		NITCVHlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gNE4xOTFizszNMi=>	NX;oUGhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3N\|I5ODlpPkKwO\|MzQDB7PD;hQi=>
PC3	NWrPUVVSS3m2b4TvfIlkcXS7IHHzd4F6		NXTkTWtCPzJiaILz		NWHVWJpGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvODF3IN88UU4>	NUPTbm5GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNVU{PDhpPkKzNlE2OzR6PD;hQi=>
PC3	NV7x[oFlS3m2b4TvfIlkcXS7IHHzd4F6		NHPOR\|U4OiCqcoO=		M2ntW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDBwMEG1N{DPxE1w	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OUK5NUc,OjN2OEmyPVE9N2F-
NFF	M2ruPWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGTIPVU4OiCqcoO=		MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjBzNkmg{txONg>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OUK5NUc,OjN2OEmyPVE9N2F-
NFF	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		M4DFXlczKGi{cx?=		M3PJ[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5HTiClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTCwMlAyPyEQvF2u	NWrNSGJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNVU{PDhpPkKzNlE2OzR6PD;hQi=>
A549	NUfZdW9[S3m2b4TvfIlkcXS7IHHzd4F6		M3n0d\|czKGi{cx?=		MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFIh\|ryPLh?=	M3\0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkG1N\|Q5Lz5{M{KxOVM1QDxxYU6=
KB	NYDJfYNvS3m2b4TvfIlkcXS7IHHzd4F6		MoPCO\|IhcHK\|		MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	MnfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MkK5OVMoRjJ4NUKyPVU{RC:jPh?=
PC3	NUGwc3lQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NE\Ydms1QCCqcoO=		NYW0UpdxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFI4PiEQvF2u	NH;QTmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzPFMzOyd-MkiwN\|g{OjN:L3G+
HEK	NGnXWYFEgXSxdH;4bYNqfHliYYPzZZk>		NYizPXlJPzJiaILz		MkjtR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGVMKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFMyKM7:TT6=	NIHJV2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVM1QCd-MkOyNVU{PDh:L3G+
HeLa	MmXuR5l1d3SxeHnjbZR6KGG\|c3H5		M3u3dVczKGi{cx?=		NVK4ZnI1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFM2QCEQvF2u	M1fBdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5NlkyLz5{M{S4PVI6OTxxYU6=
HeLa	M17uW2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3H4dlczKGi{cx?=		NVL4NXVXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUAxNjB\|NjFOwG0v	NHPPTZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KxOVM1QCd-MkOyNVU{PDh:L3G+
BT549	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkK0OFghcHK\|		NHHrSYlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA2PDd{IN88UU4>	M4j5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I{Lz5{OECzPFMzOzxxYU6=
DU145	NHzsblBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUKxe4tnPDhiaILz		MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC3NlMh\|ryPLh?=	NVKwWnBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|g{OjNpPkK4NFM5OzJ\|PD;hQi=>
Leukemia cells	NHrFRoZCdnSrdIXtc5Ih[XO\|YYm=		M2XIbVQ5KGi{cx?=		NVLBdphMSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUIV2c2WvaXGgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMTFOwG0v	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Leukemia cells	NF;ZTItCdnSrdIXtc5Ih[XO\|YYm=		MkW3OFghcHK\|		MlXlRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTHX1b4VucWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlEh\|ryPLh?=	NWG0empwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
Colon cancer cells	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=				M3;UR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{whT0l3MDC9JFAvOSEQvF2u	M330RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
Leukemia cells	M3fvcGN6fG:2b4jpZ4l1gSCjc4PhfS=>				MnLIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcIV2c2WvaXGgZ4VtdHNuIFfJOVAhRSByLkGg{txONg>?	NFPESW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
Colon cancer cells	NFHlSI1CdnSrdIXtc5Ih[XO\|YYm=		MU[0PEBpenN?		M2ewdWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPvcI9vKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6xJO69VS5?	NIi3O5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Colon cancer cells	NIjBWHNCdnSrdIXtc5Ih[XO\|YYm=		NVzTSnpQPDhiaILz		NIrpUJZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2khRSByLkGg{txONg>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Leukemia cells	MoPxRY51cXS3bX;yJIF{e2G7				NVGwc3dHSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdGW3a3XtbYEh[2WubIOsJGdKPTBiPTCwMlEh\|ryPLh?=	M3jvZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
Colon cancer cells	MkfwRY51cXS3bX;yJIF{e2G7				M{LBbGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JINwdG:wIIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4yKM7:TT6=	NXfT[VRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
Leukemia cells	NInsSoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2L6UVQ5KGi{cx?=		MVfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDs[ZVs\W2rYTDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlEh\|ryPLh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
Colon cancer cells	NXn1XVBnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXq0PEBpenN?		NYLOU2FjT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNUDPxE1w	NGDCR2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
Leukemia cells	MmPKR5l1d3SxeHnjbZR6KGG\|c3H5		M3v6SlQ5KGi{cx?=		M1nYbWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIxmfWunbXnhJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOSEQvF2u	MkXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
Colon cancer cells	NWDKOpRTS3m2b4TvfIlkcXS7IHHzd4F6		MoL4OFghcHK\|		MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zIN88UU4>	M1LPc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
Leukemia cells	NYL0ZoF1S3m2b4TvfIlkcXS7IHHzd4F6		M4S0W\|Q5KGi{cx?=		NETCVZhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBt\XWtZX3pZUBk\WyuczDh[pRmeiB2ODDodpMtKEeLNUCgQUAxNjFizszNMi=>	Ml;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
Colon cancer cells	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		M{nVRVQ5KGi{cx?=		NYLtUoJiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0:OT16gZ4VtdHNiYX\0[ZIhPDhiaILzMEBIUTVyIE2gNE4yKM7:TT6=	MofoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
MDA-MB-231	NGT6XVZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmH6OFghcHK\|		Ml\iRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjFzNk[g{txONg>?	M2\L[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEO4N\|I{Lz5{OECzPFMzOzxxYU6=
central nervous system cancer cells	NEntOmJEgXSxdH;4bYNqfHliYYPzZZk>				NI\ubWZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBk\W62cnHsJI5men[xdYOgd5l{fGWvIHPhcoNmeiClZXzsd{whT0l3MDC9JFAvOTJ3OEmg{txONg>?	M4Hp[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
prostate cancer cells	NE\jPIhEgXSxdH;4bYNqfHliYYPzZZk>				NFTjRWpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBxem:\|dHH0[UBk[W6lZYKgZ4VtdHNuIFfJOVAhRSByLkGyOVg6KM7:TT6=	M{XxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
CNS	NHiwTVlCdnSrdIXtc5Ih[XO\|YYm=		MVu0PEBpenN?		NFLWO2tCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkGyOVg6KM7:TT6=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
prostate cancer cells	MlfJRY51cXS3bX;yJIF{e2G7		MUC0PEBpenN?		NFW2OFFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvOTJ3OEmg{txONg>?	NWPN[FFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
CNS	MWHBcpRqfHWvb4KgZZN{[Xl?				M{jkcWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNPWyC2dX3vdkBk\WyuczygS2k2OCB;IECuNVI2QDlizszNMi=>	NEDFOno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
prostate cancer cells	M2nPcGFvfGm2dX3vdkBie3OjeR?=				MkW2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdJJwe3SjdHWgeJVud3JiY3XscJMtKEeLNUCgQUAxNjF{NUi5JO69VS5?	NYjZbHRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
CNS	NIr3eWJCdnSrdIXtc5Ih[XO\|YYm=		NITGZ2k1QCCqcoO=		MU\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFTmOgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLIE2gNE4yOyEQvF2u	NWq2THJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
prostate cancer cells	NYDDe5l{SW62aYT1cY9zKGG\|c3H5		MmCwOFghcHK\|		MXXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCycn;zeIF1\SClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2khRSByLkGzJO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
prostate cancer cells	M3PmXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnzXOFghcHK\|		MlXrS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gdJJwe3SjdHWgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNVMh\|ryPLh?=	NEL3dpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
CNS	M2P3V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{nsflQ5KGi{cx?=		MUPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTNizszNMi=>	NYH3d2wxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
CNS	NFvhV3FEgXSxdH;4bYNqfHliYYPzZZk>		NGC4b4Q1QCCqcoO=		NV62To85S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkGzJO69VS5?	M3[0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
prostate cancer cells	NE\ZW45EgXSxdH;4bYNqfHliYYPzZZk>		MX20PEBpenN?		M1XoNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJBzd3O2YYTlJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlE{KM7:TT6=	M3;wdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
prostate cancer cells	MlTGR5l1d3SxeHnjbZR6KGG\|c3H5		NVvsNHhkPDhiaILz		M1[3TmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJBzd3O2YYTlJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlE{KM7:TT6=	NF;YVJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
CNS	NGjxb\|VEgXSxdH;4bYNqfHliYYPzZZk>		MlLxOFghcHK\|		NHT2PG9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEVlNiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwMUOg{txONg>?	MlHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
Melanoma cells	NXvWbHNCSW62aYT1cY9zKGG\|c3H5		MUK0PEBpenN?		NELQSndCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDN[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwJF0hOC5zNUi0PUDPxE1w	NEC3eZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
Melanoma cells	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=				M2\ofmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|LDDHTVUxKD1iMD6xOVg1QSEQvF2u	M1Tx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
Melanoma cells	NXHuWm1SSW62aYT1cY9zKGG\|c3H5				M1ToW2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1mdGGwb33hJINmdGy\|LDDHTVUxKD1iMD6xOVg1QSEQvF2u	M4HNe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
Melanoma cells	MUDBcpRqfHWvb4KgZZN{[Xl?		NFrnUW41QCCqcoO=		Mnn2RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTXXsZY5wdWFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0liPTCwMlE3KM7:TT6=	M4HPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
Melanoma cells	MoTTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NWTsOJBHT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hdWWuYX7vcYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCJSUWwJF0hOC5zNjFOwG0v	NWSwfnlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
Melanoma cells	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		M2X4bFQ5KGi{cx?=		NF:0UYpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk\WyuczDh[pRmeiB2ODDodpMtKEeLNUCgQUAxNjF4IN88UU4>	Ml\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
Melanoma cells	MX;DfZRwfG:6aXPpeJkh[XO\|YYm=		MoraOFghcHK\|		M1jQcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whT0l3MDC9JFAvOTZizszNMi=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
A549	M2HYeGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFf6cnE1QCCqcoO=		M{m0[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xO\|E2KM7:TT6=	MlPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{izNlMoRjJ6MEO4N\|I{RC:jPh?=
NSCLC	MkTmRY51cXS3bX;yJIF{e2G7		NITF[VY1QCCqcoO=		MUjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQU1PMR{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTUA:KDBwMkWg{txONg>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
NSCLC	MlTKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MX:0PEBpenN?		M37aTGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuNlUh\|ryPLh?=	Mnv0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
NSCLC	M2jwe2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MmH1OFghcHK\|		MljaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6yOUDPxE1w	M{P2TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
NSCLC	NGfEXGtEgXSxdH;4bYNqfHliYYPzZZk>		MljCOFghcHK\|		MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkK1JO69VS5?	M3fDOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
NSCLC	NXroUXJoSW62aYT1cY9zKGG\|c3H5				M3WyfGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JG5US0yFIHPlcIx{NCCJSUWwJF0hOC5{NUGxPUDPxE1w	NE[1b2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
NSCLC	NIPkNXdCdnSrdIXtc5Ih[XO\|YYm=		M2[zPFQ5KGi{cx?=		NEmwVFVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4zPTFzOTFOwG0v	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
Non-small cell lung carcinoma cells	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=				Ml3FR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUo9vNXOvYXzsJINmdGxibIXu[{Bk[XKlaX7vcYEh[2WubIOsJGdKPTBiPTCwMlI2OTF7IN88UU4>	M174PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
ovarian cancer cells	NYHmZVBDS3m2b4TvfIlkcXS7IHHzd4F6				M1LCTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	NF30NYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
renal cancer cells	NYjl[ml1S3m2b4TvfIlkcXS7IHHzd4F6				MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	NFzEXGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
breast cancer cells	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=				NI\tdodEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{NCCJSUWwJF0hOC5\|MU[yN{DPxE1w	Mk\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
ovarian cancer cells	MkHtRY51cXS3bX;yJIF{e2G7		M2nmVVQ5KGi{cx?=		NFzD[41CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4{OTZ{MzFOwG0v	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
renal cancer cells	MlPMRY51cXS3bX;yJIF{e2G7		NGHzTpc1QCCqcoO=		NV\tfYJ3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	NXXKN3FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
breast cancer cells	M1TwZWFvfGm2dX3vdkBie3OjeR?=		NXLyTXJIPDhiaILz		NVPLW2NmSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4{OTZ{MzFOwG0v	MlPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyME[yPFUoRjF7MEC2Nlg2RC:jPh?=
renal cancer cells	NWjaR5VnSW62aYT1cY9zKGG\|c3H5				M2TVeWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JJJmdmGuIIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4{OTZ{MzFOwG0v	NID6bWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
ovarian cancer cells	MnXYRY51cXS3bX;yJIF{e2G7				MVHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDveoFzcWGwIIT1cY9zKGOnbHzzMEBIUTVyIE2gNE4{OTZ{MzFOwG0v	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV3OUKwOUc,OTd3NUmyNFU9N2F-
breast cancer cells	NUC2OFJiSW62aYT1cY9zKGG\|c3H5				MYDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDidoVie3RidIXtc5Ih[2WubIOsJGdKPTBiPTCwMlMyPjJ\|IN88UU4>	NVru[HBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
ovarian cancer cells	NX:1THEySW62aYT1cY9zKGG\|c3H5		MVi0PEBpenN?		M1XrXGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKKD1iMD6zNkDPxE1w	M3vJ[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
renal cancer cells	M1nxfmFvfGm2dX3vdkBie3OjeR?=		NWLZV2p4PDhiaILz		MX7BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiC{ZX7hcEBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1mgQUAxNjN{IN88UU4>	NWT4SZd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
breast cancer cells	NF\pb2FCdnSrdIXtc5Ih[XO\|YYm=		M{XnXlQ5KGi{cx?=		M4Dv[mFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLy[YF{fCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2khRSByLkOyJO69VS5?	NYDYXlNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
renal cancer cells	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NF7ifYg1QCCqcoO=		M3\o[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJJJmdmGuIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	NHzr[ng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
breast cancer cells	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3Tyb\|Q5KGi{cx?=		Mn7ZS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	M2XvU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
ovarian cancer cells	NGn3cJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3nOb\|Q5KGi{cx?=		NFnBfm9Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBQfmG{aXHuJINidmOncjDj[YxteyCjZoTldkA1QCCqcoOsJGdKPTBiPTCwMlMzKM7:TT6=	M2fq[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
breast cancer cells	NGGxd\|FEgXSxdH;4bYNqfHliYYPzZZk>		M1\zcVQ5KGi{cx?=		NHTVc21EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	NWP2PHdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
renal cancer cells	NXHiToNjS3m2b4TvfIlkcXS7IHHzd4F6		MkGzOFghcHK\|		MnLIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiR1m1NEA:KDBwM{Kg{txONg>?	M4\iclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
ovarian cancer cells	NHP6eI9EgXSxdH;4bYNqfHliYYPzZZk>		M{n5dFQ5KGi{cx?=		MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
renal cancer cells	M{jzSmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGi3co01QCCqcoO=		NHTXTJdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBz\W6jbDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDHTVUxKD1iMD6zNkDPxE1w	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
ovarian cancer cells	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		M1H1SFQ5KGi{cx?=		MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIFfJOVAhRSByLkOyJO69VS5?	M{fEcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkizOFMxLz5{MkK4N\|Q{ODxxYU6=
breast cancer cells	NUTyW4h6S3m2b4TvfIlkcXS7IHHzd4F6		MXW0PEBpenN?		NHLweopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygS2k2OCB;IECuN\|Ih\|ryPLh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Lu1	MnOyR5l1d3SxeHnjbZR6KGG\|c3H5		NInRNnI4OiCqcoO=		NWP2cmxWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVHVzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjR6IN88UU4>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV{Mkm1N{c,OjZ3MkK5OVM9N2F-
MCF7	M1WxemN6fG:2b4jpZ4l1gSCjc4PhfS=>		MWq3NkBpenN?		MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlUyKM7:TT6=	M{H3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUKyPVU{Lz5{NkWyNlk2OzxxYU6=
HepG2	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		M3fHRlczKGi{cx?=		NHTvdo5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC54OTFOwG0v	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV{Mkm1N{c,OjZ3MkK5OVM9N2F-
COLON	Mk\LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEiyT241QCCqcoO=		NHPOXIRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB\|Lkm4JO69VS5?	NGjTTmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
COLON	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=		MmOyOFghcHK\|		MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUA{Njl6IN88UU4>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
COLON	NGrC[lVEgXSxdH;4bYNqfHliYYPzZZk>		MWW0PEBpenN?		Ml7LR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR29NV05iY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB\|Lkm4JO69VS5?	NF21d5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
COLON	M4TRbGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NFHyTIdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMtKFSJSTC9JFMvQThzMEeg{txONg>?	NGfnd5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
COLON	MlPURY51cXS3bX;yJIF{e2G7		NYfkPIFEPDhiaILz		NE[2[3ZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygWGdKKD1iMz65PFExPyEQvF2u	M3PS[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEC2Nlg2Lz5zOUCwOlI5PTxxYU6=
COLON	NIjReW1CdnSrdIXtc5Ih[XO\|YYm=				MUXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDjc4xwdiC2dX3vdkBk\WyuczygWGdKKD1iMz65PFExPyEQvF2u	MnXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NUmyNFUoRjF5NUW5NlA2RC:jPh?=
central nervous system cancer cells	M33GOGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NIT6fWtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBk\W62cnHsJI5men[xdYOgd5l{fGWvIHPhcoNmeiClZXzsd{whXEeLIE2gOk4{ODl3NzFOwG0v	M3eyT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUm4NFE5Lz5zOEW5PFAyQDxxYU6=
prostate cancer cells	NXL1WFQ4S3m2b4TvfIlkcXS7IHHzd4F6				NYj5[HViS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|LDDUS2khRSB4LkOwPVU4KM7:TT6=	Ml6yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
CNS	MlX1RY51cXS3bX;yJIF{e2G7		Mn7NOFghcHK\|		M4mxUmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPOV{Bk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiVFfJJF0hPi5\|MEm1O{DPxE1w	NUD2bJZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
prostate cancer cells	NY[1[45KSW62aYT1cY9zKGG\|c3H5		MojoOFghcHK\|		MojxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5icILvd5RifGViY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJHRIUSB;IE[uN\|A6PTdizszNMi=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTByNkK4OUc,OTlyME[yPFU9N2F-
CNS	Mof1RY51cXS3bX;yJIF{e2G7				M2f0ZmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNPWyC2dX3vdkBk\WyuczygWGdKKD1iNj6zNFk2PyEQvF2u	NUfuTpNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
prostate cancer cells	MmjURY51cXS3bX;yJIF{e2G7				MnTMRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgdJJwe3SjdHWgeJVud3JiY3XscJMtKFSJSTC9JFYvOzB7NUeg{txONg>?	NUjNNndMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
prostate cancer cells	M1HGfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV\tbHpFPDhiaILz		NWDZWXpMT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4heHKxc4TheIUh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gOk4{OSEQvF2u	M2HnR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
CNS	Mnq4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkDEOFghcHK\|		M2H0UWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGNPWyClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUA3NjNzIN88UU4>	MoHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1PVkoRjJyNki0OVk6RC:jPh?=
CNS	Ml7mR5l1d3SxeHnjbZR6KGG\|c3H5		NXPIRVB[PDhiaILz		NYfyWmxNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS06VIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDZwM{Gg{txONg>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
prostate cancer cells	M{\EVWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4K3T\|Q5KGi{cx?=		MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB4LkOxJO69VS5?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
prostate cancer cells	MkDkR5l1d3SxeHnjbZR6KGG\|c3H5		MUK0PEBpenN?		MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdo9{fGG2ZTDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSB4LkOxJO69VS5?	NEjaT5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK4N\|Q{OCd-MkKyPFM1OzB:L3G+
CNS	NITVOpREgXSxdH;4bYNqfHliYYPzZZk>		NHixW3Q1QCCqcoO=		MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDUnMh[2GwY3XyJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gOk4{OSEQvF2u	MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
Melanoma cells	M2Hxc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFjafmI1QCCqcoO=		NH3uUpRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBu\Wyjbn;tZUBk\WyuczDh[pRmeiB2ODDodpMtKFSJSTC9JFcvQTRizszNMi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
breast cancer cells	NIPRepVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH7D[XE1QCCqcoO=		NIq0XVJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iNz65OEDPxE1w	NInmWJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
breast cancer cells	MnHkR5l1d3SxeHnjbZR6KGG\|c3H5		MW[0PEBpenN?		MlvRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDdwOUSg{txONg>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
Melanoma cells	M2TrSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3XNc\|Q5KGi{cx?=		M2PJXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINmdGy\|IHHmeIVzKDR6IHjyd{whXEeLIE2gO{46PCEQvF2u	M3fmVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{S3O\|Q6Lz5{NEe0O\|c1QTxxYU6=
Melanoma cells	M{XNR2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M1y0SFQ5KGi{cx?=		NHnMbGFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk\WyuczDh[pRmeiB2ODDodpMtKFSJSTC9JFcvQTRizszNMi=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
breast cancer cells	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=		NHKwXWM1QCCqcoO=		MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHzzJIFnfGW{IES4JIhzeyxiVFfJJF0hPy57NDFOwG0v	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6M{SzNEc,OjJ{OEO0N\|A9N2F-
Melanoma cells	NWrVeIJ{SW62aYT1cY9zKGG\|c3H5		M4LudlQ5KGi{cx?=		NIrDVlBCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDN[Yxidm:vYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCWR1mgQUA4Njl2M{K4JO69VS5?	NXrIe4IxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
Melanoma cells	M3S4bmN6fG:2b4jpZ4l1gSCjc4PhfS=>				MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDt[Yxidm:vYTDj[YxteyxiVFfJJF0hPy57NEOyPEDPxE1w	NELWPXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
breast cancer cells	NF2y[4xEgXSxdH;4bYNqfHliYYPzZZk>				MmHCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsd{whXEeLIE2gO{46PDN{ODFOwG0v	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
breast cancer cells	M3fhTmFvfGm2dX3vdkBie3OjeR?=		M{W4dlQ5KGi{cx?=		NVfOToQ4SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRpJm[XO2IHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTC3Mlk1OzJ6IN88UU4>	NXvHTlVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
Melanoma cells	NULDS2MzSW62aYT1cY9zKGG\|c3H5				NILOXW9CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBu\Wyjbn;tZUBk\WyuczygWGdKKD1iNz65OFMzQCEQvF2u	NILmUoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
breast tumor cells	MV7BcpRqfHWvb4KgZZN{[Xl?				MX\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDidoVie3RidIXtc5Ih[2WubIOsJHRIUSB;IEeuPVQ{OjhizszNMi=>	NX7pUlZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
NSCLC	NVHaTZlKSW62aYT1cY9zKGG\|c3H5				NUn4OFMzSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhVlOFTFOgZ4VtdHNuIGTHTUA:KDF3Lki0PFkh\|ryPLh?=	M1riNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUW5NlA2Lz5zN{W1PVIxPTxxYU6=
Leukemia cells	MX3BcpRqfHWvb4KgZZN{[Xl?		MWS0PEBpenN?		MWHBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOZYXr[Y1q[SClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTCxOU45PDh7IN88UU4>	NGSyNVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
NSCLC	MUPBcpRqfHWvb4KgZZN{[Xl?		MmW1OFghcHK\|		NH7ydWJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTCxOU45PDh7IN88UU4>	NVrJPXM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNFYzQDVpPkG5NFA3Ojh3PD;hQi=>
Non-small cell lung carcinoma cells	Mn\VR5l1d3SxeHnjbZR6KGG\|c3H5				MkTrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUo9vNXOvYXzsJINmdGxibIXu[{Bk[XKlaX7vcYEh[2WubIOsJHRIUSB;IEG1Mlg1QDlizszNMi=>	NEjoS\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW5PFAyQCd-MUi1PVgxOTh:L3G+
Leukemia cells	M{Pr[GN6fG:2b4jpZ4l1gSCjc4PhfS=>				MojWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcIV2c2WvaXGgZ4VtdHNuIGTHTUA:KDF3Lki0PFkh\|ryPLh?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV7OECxPEc,OTh3OUiwNVg9N2F-
Leukemia cells	MnG3RY51cXS3bX;yJIF{e2G7				MkWzRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcIV2c2WvaXGgZ4VtdHNuIGTHTUA:KDF3Lki0PFkh\|ryPLh?=	NVX1e2V[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
NSCLC	M3jLNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIrldWU1QCCqcoO=		Mn3WS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUnNEVENiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzNT64OUDPxE1w	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW5PUc,OjB4OES1PVk9N2F-
Leukemia cells	MnXvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1nUNlQ5KGi{cx?=		MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDs[ZVs\W2rYTDj[YxteyCjZoTldkA1QCCqcoOsJHRIUSB;IEG1Mlg2KM7:TT6=	M170NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNki0OVk6Lz5{ME[4OFU6QTxxYU6=
NSCLC	NIP3R3JEgXSxdH;4bYNqfHliYYPzZZk>		M{i0WFQ5KGi{cx?=		M2XDdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5US0yFIHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUWuPFUh\|ryPLh?=	MmTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
Leukemia cells	NVKwSmszS3m2b4TvfIlkcXS7IHHzd4F6		Mk\ZOFghcHK\|		NXL6VIE2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdGW3a3XtbYEh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyPS56NTFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
NSCLC	NX7JS\|VSS3m2b4TvfIlkcXS7IHHzd4F6		NFjoWoQ1QCCqcoO=		MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOV2NNSyClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF3Lki1JO69VS5?	NVTqWmZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFc4PDlpPkK0O\|Q4PzR7PD;hQi=>
Leukemia cells	NX3mTGVpS3m2b4TvfIlkcXS7IHHzd4F6		NYPIemNZPDhiaILz		NF7DRpVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBt\XWtZX3pZUBk\WyuczDh[pRmeiB2ODDodpMtKFSJSTC9JFE2Njh3IN88UU4>	NX;lNVNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFM1OzBpPkKyNlg{PDNyPD;hQi=>
renal cancer cells	M1zuW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmH3OFghcHK\|		NHjrSYtIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBz\W6jbDDjZY5k\XJiY3XscJMh[W[2ZYKgOFghcHK\|LDDUS2khRSBzOT65OUDPxE1w	NEPyXGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[4OFU6QSd-MkC2PFQ2QTl:L3G+
ovarian cancer cells	NWrvR3Z6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVGySppRPDhiaILz		MVfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPeoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNuIGTHTUA:KDF7Lkm1JO69VS5?	NXnZT2FuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFQ2QTlpPkKwOlg1PTl7PD;hQi=>
renal cancer cells	Mn3ZR5l1d3SxeHnjbZR6KGG\|c3H5		NVnrXJA4PDhiaILz		MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDy[Y5idCClYX7j[ZIh[2WubIOgZYZ1\XJiNEigbJJ{NCCWR1mgQUAyQS57NTFOwG0v	Mkm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEe3OFkoRjJ2N{S3O\|Q6RC:jPh?=
ovarian cancer cells	MmK5R5l1d3SxeHnjbZR6KGG\|c3H5		MXe0PEBpenN?		NVi3O\|h{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgZ4VtdHNiYX\0[ZIhPDhiaILzMEBVT0liPTCxPU46PSEQvF2u	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2N{e0PUc,OjR5NEe3OFk9N2F-
renal cancer cells	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=		NEWybYg1QCCqcoO=		NYfueJJSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hemWwYXygZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUmuPVUh\|ryPLh?=	Ml7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
ovarian cancer cells	MknJR5l1d3SxeHnjbZR6KGG\|c3H5		MYW0PEBpenN?		M4nqe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIx{KGGodHXyJFQ5KGi{czygWGdKKD1iMUmuPVUh\|ryPLh?=	MlHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{OEO0N\|AoRjJ{MkizOFMxRC:jPh?=
ovarian cancer cells	NVXVXpRVS3m2b4TvfIlkcXS7IHHzd4F6				NWXVdmZYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgZ4VtdHNuIGTHTUA:KDF7Lkm1NlYh\|ryPLh?=	MlHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
renal cancer cells	NHfofHREgXSxdH;4bYNqfHliYYPzZZk>				Mkf5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdoVv[WxiY3HuZ4VzKGOnbHzzMEBVT0liPTCxPU46PTJ4IN88UU4>	MmDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3OUiwNVgoRjF6NUm4NFE5RC:jPh?=
ovarian cancer cells	NX\KcHVvSW62aYT1cY9zKGG\|c3H5		MWe0PEBpenN?		NEi3dYxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBVT0liPTCxPU46PTJ4IN88UU4>	NInLOoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal cancer cells	M2G3U2FvfGm2dX3vdkBie3OjeR?=		NHHMW3c1QCCqcoO=		M4fEW2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIILlcoFtKGOjbnPldkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDUS2khRSBzOT65OVI3KM7:TT6=	NIPFZYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCwOlI5PSd-MUmwNFYzQDV:L3G+
renal tumor cells	NWnOUmh5SW62aYT1cY9zKGG\|c3H5				MWDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDy[Y5idCC2dX3vdkBk\WyuczygWGdKKD1iMUmuPVUzPiEQvF2u	NWX6bFNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OVkzODVpPkG3OVU6OjB3PD;hQi=>
ovarian tumor cells	NHK2fnZCdnSrdIXtc5Ih[XO\|YYm=				MonHRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4Sgc5ZiemmjbjD0eY1weiClZXzsd{whXEeLIE2gNVkvQTV{NjFOwG0v	NHrBOYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1PVIxPSd-MUe1OVkzODV:L3G+
PC3	MoPPR5l1d3SxeHnjbZR6KGG\|c3H5		NEP6Vms1QCCqcoO=		M{XwPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{OD6xNUDPxE1w	NXzWWXVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|Q5OTZpPkK5NVc1QDF4PD;hQi=>
neural precursor cells	MX;GeY5kfGmxbjDhd5NigQ>?				NYHUc\|JSUW6qaXLpeIlwdiCxZjDu[ZVzd3OyaHXy[UBxem:uaX\ldoF1cW:wIH;mJI1wfXOnIH7leZJidCCycnXjeZJ{d3JiY3XscJMh[nliTWTUJIF{e2G7	Mn\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUe2N\|EoRjF5NEG3OlMyRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

In vivo

Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. ^[6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . ^[7]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: B16 melanoma cell
Concentrations: 10 nM
Incubation Time: 3 days
Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human rhabdomyosarcoma xenografts Rh12
Dosages: 3 mg/kg
Administration: A single i.p. administration
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vincristine (NSC-67574) sulfate SDF

Molecular Weight	923.04
Formula	C₄₆H₅₈N₄O₁₄S
CAS No.	2068-78-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Leurocristine, Oncovin, 22-Oxovincaleukoblastine
Smiles	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04448834	Not yet recruiting	Drug: Blinatumomab	B-cell Acute Lymphoblastic Leukemia	David Rizzieri MD\|Amgen\|Acrotech Biopharma LLC\|Duke University	April 1 2021	Phase 2
NCT02360930	Unknown status	--	Leukemia Acute Lymphoblastic\|Leukemia	Children''s Hospital Los Angeles	September 2014	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
Answer:
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine (NSC-67574) sulfate